Nuclear localization of GSK3β and p65 predict AML survival. (A) Nuclear localization scores of p65 were quantified using imaging cytometry (n = 86). A box-and-whisker plot displaying the median and quartile distributions is shown. (B-C) Kaplan-Meier survival curve analysis comparing overall survival of AML patients based on nuclear localization scores of GSK3β (B) or p65 (C) above and below the median. (D) Nuclear localization scores of GSK3β and p65 were correlated to patient survival using multivariate Cox proportional hazard analysis controlling for age, sex, treatment group, and performance status (n = 86). Nuclear GSK3β localization improves a multivariate Cox proportional hazards model for overall survival. (E) Nuclear localization scores of GSK3β were correlated to patient complete remission and disease-free survival using a logistic regression model (n = 86). Increased GSK3β is associated with less DFS and trended to less CR (HR = 2.784 and 0.262, P = .019 and 0.067, respectively). (F) Analysis controlling for age, performance status, and treatment was performed both without and with GSK3β (top and bottom panels, respectively). The likelihood ratio is 9.1 (degrees of freedom = 1, P = .0026, n = 86) indicating the model including GSK3β as a covariate significantly improves the model fit to the data.